From the publishers of The New England Journal of Medicine
Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.
Some content may require paid access to the site. Subscribe or
purchase a seven-day site pass for the full text of
all our clinical perspectives on medical journal articles, guidelines, and news.
The new label outlines an increased risk for abnormal heart rhythms when saquinavir is used with ritonavir.
The new formulation should improve the usability of boosted PIs in resource-limited settings.
The new indication maximizes the number of patients who could benefit from maraviroc, but many clinicians and patients will likely opt for agents that are simpler to use.
Severe skin or hypersensitivity reactions should prompt immediate cessation of the drug.
The revision reflects the drugs potential for prolonging both the PR interval and the QT interval.
Approval is based on a 48-week comparison of ritonavir-boosted darunavir with lopinavir/ritonavir.
Nelfinavir can once again be prescribed to children and pregnant women.
Cefixime tablets (Suprax; 400 mg) are now available in the U.S. for the first time since 2002. Cefixime is the only CDC-recommended oral treatment for . . .
The FDA has issued an early communication citing the potential association between use of abacavir or ddI and increased risk for myocardial infarction (MI). The . . .
The revision reflects the drugs potential for hepatotoxicity.